CURRICULUM VITAE



CURRICULUM VITAE

KIMBERLY A. SKELDING MD

PERSONAL DATA:

Name: Kimberly A. Skelding MD FACC, FAHA, FSCAI

Birthdate/place: October 30, 1969; Mt. Carmel Pennsylvania

Citizenship: USA

Professional Address: Geisinger Medical Center

Department of Cardiology

100 North Academy Avenue

Danville, PA 17822

Phone: (570) 271-6177

Email: kaskelding@geisinger.edu

POSITIONS HELD:

Geisinger Medical Center

Associate, Interventional Cardiology

Director Cardiovascular Research

Geisinger Health System

Director Cardiovascular Genomics

Henry Hood Center for Health Research

Director, Women’s Heart and Vascular Health Program

Danville, PA

August 2005-Present

Temple University School of Medicine

Clinical Assistant Professor

2008-present

National Human Genome Research Institute

Bethesda, Maryland

Special Volunteer

Laboratory of Dr. Elizabeth Nabel

July 2004 to 2009

National Heart, Lung, and Blood Institute

Protocol Specialist

Laboratory of Dr. Elizabeth Nabel

Bethesda, Maryland

July 2001 to June 2004

Mayo Clinic, Rochester, MN

Assistant Professor of Medicine

2005

Interventional Fellow

July 2003-June 2005

Mayo Graduate School, Rochester, MN

Master’s Degree in Clinical Research Candidate

Dr. Ralph and Marian C. Falk Medical Research Trust Fellowship

July 2002-June 2004

William Beaumont Hospital, Royal Oak, MI

Clinical Cardiology Fellow

July 1999-June 2002

Penn State Geisinger Medical Center, Danville, PA

Resident, Internal Medicine

July 1996-June 1999

Northwestern University School of Medicine, Chicago, IL

Doctorate in Medicine

August 1992-May 1996

Franklin and Marshall College, Lancaster, PA

Bachelor of Arts

August 1988-May 1991

CLINICAL SKILLSET & TRAINING:

1. Transcatheter Aortic Valve Replacement

2. Percutaneous Coronary Intervention

3. Alcohol Septal Ablation

4. Balloon Valvuloplasty

5. Radial Artery Catheterization and Intervention

6. Left Atrial Appendage Occlusion Device

7. Patent Foramen Ovale Closures

8. Myocardial Biopsy

9. Transeptal catheterization

10. Hemodynamic Evaluation

11. Coronary Artery Fistula Closure

CAREER DEVELOPMENT:

1. American College of Physician Executives, Winter Institute 2009

▪ Finance in Health Care Organization

▪ Valuable Communication Skills

▪ Management Skills for Physician Executive

▪ Marketing and Strategic Planning

▪ Increasing Your Influence

▪ Negotiation

2. Physician Leadership Development Program, 2007 – 2008

▪ Comprehensive program to develop and foster leadership through didactic and interactive learning

3. Executive Coaching Program – Leadership Forward, 2007-2208

▪ 360 degree evaluation of leadership strengths and challenges

▪ Formal one-on-one leadership coaching by an outside firm

4. Women’s Career and Leadership Development Conference, American College of Cardiology Foundation, Dallas TX. February 2007

GRANT SUPPORT:

1. Weis Foundation Grant, $50,000, 2009.

2. 2006 Targeted Research Grant, Genomics of In-Stent Restenosis, Geisinger Foundation, $94,000

3. 2006 Stinebring Foundation for Women’s Cardiovascular Health Project, $300,000

4. 2006 Degenstein Grant, Women’s Cardiovascular Health Project, Geisinger Medical Center $24,000

5. Cardiogene Study NHLBI Contract Grant Funding

6. July 2002-June 2003, Dr. Ralph and Marian C. Falk Medical Research Trust Fellowship Full Salary and Tuition Support for Master’s in Clinical Research

7. 2001 Littman Scholarship American College of Cardiology

8. 2001 Aventis American College of Cardiology Grant

9. 2000 American Heart Association Women in Cardiology Grant

10. 2000 Berlex Educational Grant

11. 1993 Children’s Memorial Institute for Educational Research Grant

12. 1990 Weis Center for Research Pre-Doctoral Training Grant

HONORS:

1. Board of Trustee Member, Society for Cardiovascular Angiography and Intervention 2009-2012.

2. Fellow of the Society for Cardiovascular Angiography and Intervention 2007

3. Fellow of the American College of Cardiology 2006

4. Fellow of the American Heart Association 2006

5. Exceptional Clinician Educator, Top 10%, 2006

6. Clinical Research 2005 Outstanding Trainee Award, Clinical Research 2005 Meeting

7. Dr. William and Marian C. Falk Medical Research Trust Fellowship for Physicians Demonstrating Promise in Clinical Research

8. 2001 William Beaumont Hospital Research Forum Finalist

9. 2001 Michigan American College of Cardiology Clinical Vignette Competition Finalist

10. 2001 Michigan American College of Cardiology Research Competition Finalist and First Runner Up

11. 2000 American College of Cardiology Henry I. Russek Award

12. 2000 William Beaumont Hospital Research Forum Finalist

13. 1988-1991 Dana Scholar, Franklin and Marshall College

ADMINISTRATIVE DUTIES:

1. Women In Innovations, Education Project Area co-chair, 2011-present.

2. Director, Geisinger Heart Institute Research Council, 2010-present.

3. Director of Cardiovascular Research, Geisinger Health System.

4. Women’s Advisory Board Member, Abbott Vascular 2010.

5. Department of Nursing Advisory Council, Bloomsburg University 2010.

6. Director, Women’s Heart and Vascular Health Program, 2005-present.

7. Director Cardiovascular Genomics and Cardiovascular Research Henry Hood Center for Health Research, 2005-present.

8. Director, Women and Interventional Cardiology Conference, 2009.

9. Board of Trustees, Society for Cardiovascular Angiography and Intervention, 2008-present.

10. Chair, Society for Cardiovascular Angiography and Intervention Radial Arterial Catheterization Sub-Committee, 2009 to present.

11. Member, Comparative Effectiveness Work Group, Society for Cardiovascular Angiography and Intervention, 2008-2009.

12. Member, Women In Innovations Committee of Society for Cardiovascular Angiography and Intervention Annual Sessions 2009

13. Faculty, Society for Cardiovascular Angiography and Intervention Annual Sessions 2009

14. Faculty, American College of Cardiology Annual Sessions 2009

15. American Heart Association Internation Liason Committee on Resuscitation Acute Coronary Syndromes/Myocardial Infarction Guidelines Committee, 2008-present.

16. American College of Physicians Regional Abstract Selection Committee

17. Co-Chair Cath lab tech standard committee of Society for Cardiovascular Angiography and Interventions, 2007-2010.

18. Women’s Cardiovascular Slideset in Coronary Artery Disease, Update Committee 2007-2008.

19. Section Editor, Acute Coronary Syndromes Journal, 2007-2010.

20. SCAI – Interventional Fellows Grant Program, 2008- 2009.

21. Section Editor, “What’s New in Interventional Cardiology” & “Hot Topics in Interventional Cardiology”, seconds-, Health Professionals Website, 2008 – present.

22. SCAI/GE Interventional Fellows Research Grant Program; Grant Reviewer 2007-2010.

23. Faculty, Cath Lab Basics Course 2007-2009.

24. Biomedical Engineering Senior Design Mentor, Bucknell University, Lewisburg, PA 9/2007 – 2010

▪ Provide biomedical, clinical and/or technical advice to senior design team on a year long project to develop or enhance biomedical devices designed to meet a clinical need.

25. Moderator, American Heart Association Scientific Sessions, November 2007.

26. Proven Care PCI Committee member 2007-2010.

▪ Identify best practice standards of care for elective percutaneous coronary intervention; Develop process, facilitate and implement program to improve patient outcomes.

27. American Heart Association Abstract Grader 2007-2010.

28. Genomic Core Lab Director for Dynamic Registry Wave 5, 2005- present.

29. Society for Cardiovascular Angiography and Interventions Career Development Committee, co-chair, February 2005-2010.

30. Executive Search Committee for Chief Research Officer, Clinical Trials - 2006.

▪ Identify and interview candidates for executive position

31. Fellowship Selection, Geisinger Medical Center, 2005 – present.

32. Director of Women’s Cardiovascular Health Initiative, Geisinger Clinic 2005- present.

▪ Develop mission, action plan and implementation of holistic program to identify risk factors, provide prevention and treat coronary artery disease.

33. Director of Cardiovascular Genomics Initiative, Geisinger Clinic 2005- present.

▪ Develop protocol, provide hypothesis and implement program for cardiovascular DNA biobanking

34. Scheduling of Interventional Fellows Coverage and Call, Mayo Clinic

35. Scheduling of Outreach Coverage, Mayo Clinic

36. Fellows Visiting Professor 2005, co-chair

37. Cardiac Rehabilitation Lecture Series, Coordinator and Lecturer1999-2002

38. Cardiology Fellowship Selection Committee, William Beaumont Hospital, Fall, 2000-2001

39. Clinical Events Committee, Senior PAMI, October 1, 2001

40. Fellowship Journal Club Coordinator 1999-2002

RESEARCH INTERESTS: Outcomes following Percutaneous Coronary Intervention; Clinical Risk modeling; Genomics of Coronary atherosclerosis, In-Stent restenosis, gender-based outcomes in coronary artery disease; Gene-environment interactions.

CLINICAL INTERESTS: Interventional cardiology, new device therapies, valvular heart disease.

RESEARCH EXPERIENCE:

1. BOSS: Evaluation of Sodium Bicarbonate to Reduce Contrast-Induced Chronic Kidney Injury in Subjects with Advanced Chronic Kidney Disease (CKD) who are Undergoing Angiography, Current.

2. Corevalve: Medtronic CoreValve® U. S. Pivotal Trial, Current.

3. C-Port: The Atlantic C-Port Trial, Current.

4. Desert: Drug Eluting Stent Event Registry of Thrombosis, Current.

5. Dynamic Registry: Dynamic Registry-Genomics Care Lab Substudy, Current.

6. Phoenix: A clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention, Current.

7. Promise: Prospective Multi-Center Imaging Study for Evaluation of Chest Pain, Current.

8. TRANSLATE ACS: Treatment with ADP Receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (Translate-ACS) Registry, Current.

9. Verdict: A Prospective, Global, Multicenter, Non-Blinded Study in patients with intermediate coronary lesions to examine the correlation between fractional flow reserve (FFR) and intravascular ultrasound with virtual histology (VH-IVUS) verdict, Current.

10. VISTA 16: Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes, Current.

11. INFUSE AMI: A 2x2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior st-segment elevation myocardial infarction (Infuse-AMI), Current.

12. HCRI DAPT: A prospective, multi-center, randomized, multicenter, single-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions, Current.

13. EDUCATE: Endeavor drug eluting stenting: Understanding care, antiplatelet agents and thrombotic events, Current.

14. ANGEL: ALERTS (AngeLmed for Early Recognition and Treatment of STEMI) Study, Current.

15. SPIRIT PRIME: A clinical evaluation of the XIENCE PRIME™ and XIENCE PRIME™ LL everolimus Eluting Coronary Stent System, Completed.

16. CHAMPION: A Clinical Trial Comparing Treatment with Cangrelor (in Combination with Usual Care) To Usual Care, In Subjects Who Require Percutaneous Coronary Intervention, Sub-Investigator, Completed.

17. AQUARIUS: A 104 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy, Sub-Investigator, Completed.

18. PARIS: Pattern of Non-Adherence to Anti-Platelet Regimens in Stented Patients an Observational Single Arm Study, Sub-Investigator, Current.

19. VIRGO: Variation In Recovery: Role Of Gender On Outcomes of Young Acute Myocardial Infarction (AMI) Patients, Principal Investigator, Current.

20. TRACER: A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome. (TRA∙CER), Sub-Investigator, Current

21. XIENCE USA: XIENCE V ™Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study, Principal Investigator, Completed.

22. ENDEAVOR SVS: The Endeavor Small Vessel Stenting (SVS) Registry – A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single DE NOVO Lesions in Small Diameter Native Coronary Arteries. Principal Investigator, Competed.

23. GRAVITAS: Gauging Responsiveness with a Verify now Assay – Impact on Thrombosis and Safety (GRAVITAS), Sub-Investigator, Completed.

24. PARACHUTE: United States Peructaneous Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease (US PARACHUTE), Sub-Investigator, Completed.

25. PROTECT II: A Prospective, Multi-Center, Randomized Controlled Trial of the IMPELLA® Recover® LP 2.5 System Versus Intra Aortic Balloon Pump (IABP) in Patients Undergoing Non Emergent High Risk PCI, Principal Investigator, Completed.

26. RECOVER II: A Prospective Randomized Trial Investigating the use of Impella® Recover® LP 2.5 System in Patients with Acute Myocardial Infarction Induced Hemodynamic Instability, Sub-Investigator, Completed.

27. RAGADO: A Phase 2a, Multi-Center, Open Label, Randomized, Feasibility and Safety Study Comparing the REG1 Anticoagulation System with Unfractionated Heparin in Subjects with Coronary Artery Disease Who Are Undergoing Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel and Aspirin., Sub-Investigator, Completed.

28. PROTECTION AMI: Inhibition of δ-Protein Kinase C for the Reduction of Infarct Size in Acute Myocardial Infarction. Sub-Investigator, Completed.

29. RESOLUTE: A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm – The Medtronic RESOLUTE US Clinical Trial. Principal Investigator, Completed.

30. REVEAL: Randomized, Multi-Center, Double-Blind, Placebo Controlled Trial of the Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Acute Myocardial Infarctions. Sub-Investigator, Completed.

31. SATURN: Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) A 104-week, Randomized, Double-Blind, Parrallel Group, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40mg or artovastatin 80mg on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Patients with Coronary Artery Disease. Sub-Investigator, Completed.

32. SPIRIT SV: Spirit Small Vessel Registry a Clinical Evaluation of the 2.25mm XIENCE V™ Everolimus Eluting Coronary Stent System. Principle Investigator, Completed

33. SPIRIT IV Clinical Trial: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with De Novo Native Coronary Artery Lesions. Geisinger Medical Center, Principal Investigator, Completed.

34. ERASE MI: A Randomized Trial to Evaluate the Effect of Adjunctive Antiplatelet Therapy with Intravenous PRT060128, A Selective P2Y12-Receptor Inhibitor, Before Primary Percutaneous Intervention in Patients With ST-Elevation Myocardial Infarction. Geisinger Medical Center, Sub-Investigator, Completed.

35. EVENT REGISTRY: A Multicenter Registry for the Evaluation of Drug Eluting Stents and Ischemic Events. Geisinger Medical Center, Principal Investigator, Completed.

36. AWARE- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of AD5FGF-4 In Female Patients with Stable Angina Pectoris who are not candidates for Revascularization. Geisinger Medical Center, Principal Investigator, Completed.

37. SONOMA - The Nexstent® Carotid Stent System: A Post Market Approval Evaluation Study In Conjunction With The Boston Scientific Filterwire EZ™ Embolic Protection System. Geisinger Medical Center, Sub-Investigator, Completed.

38. ISAR 3 - Intracoronary Stenting And Antithrombotic Regimen: Rapid Early Action For Coronary Treatment-ISAR-REACT-3 - Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial Of Bivalirudin And Infractionated Heparin In Patients Undergoing Percutaneous Coronary Intervention. Geisinger Medical Center, Sub-Investigator, Completed.

39. ISAR 4 - Intracoronary Stenting And Antithrombotic Regimen: Rapid Early Action For Coronary Treatment-ISAR-REACT-4 - Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial Of Abciximab And Bivalirudin In Patients With Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Geisinger Medical Center, Sub-Investigator, Completed.

40. PLATO – A Study of PLATelet inhibition and Patient Outcomes – A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS). Geisinger Medical Center, Sub Investigator, Completed.

41. Registry and Biobanking of Patients with Angina and Normal Coronary Arteries/Minimal Atherosclerotic Disease for Markers of Progression in Women. Geisinger Medical Center, Principal Investigator, Ongoing.

42. Demography of AMI – Acute Myocardial Infarction in a Rural Tertiary Care Center. Geisinger Medical Center, Principal Investigator, Ongoing.

43. Genomics of Cardiovascular Disease and Adverse Outcomes Following PCI. Geisinger Medical Center, Principal Investigator, Ongoing.

44. Outcomes of Women Following Cardiovascular Risk Factor Intervention. Geisinger Medical Center Principal Investigator, Ongoing.

45. CardioGene – Gene Expression Profiling for Markers of In-Stent Restenosis National Institute of Health, Bethesda, MD Elizabeth Nabel MD, Mentor Multi-Center Trial Primary Investigator, In follow up.

46. NHLBI PTCA Dynamic Registry Wave 5 Genomic Core Lab. Geisinger Medical Center Principal Investigator, In follow up.

47. Protect AFIB - Watchman® Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation. Principal Investigator, In follow up.

48. Percutaneous Coronary Intervention Long Term Events Registry. Geisinger Clinic Principal Investigator, Ongoing.

49. Appraise: A PHASE 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome. Geisinger Medical Center, Principal Investigator, Completed.

50. Sepia PCI A Randomized, Double-Blind, Triple-Dummy Dose-Ranging Study Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban in Patients with NON-ST Elevation Acute Coronary Syndrome and Planned Early Invasive Strategy. Geisinger Medical Center, Principal Investigator, Completed

51. HORIZON – AMI - Harmonizing Outcomes with Revascularization and Stents-A Dual arm factorial randomized trial in patients with ST segment elevation. AMI to compare the results of using either anticoagulation with unfractionated Heparin plus routine GPIIB/IIIA Inhibition with Bivalirudin and bail-out GP IIB/IIIA inhibition, and primary angioplasty with stent implantation with either a slow rate-release Paclitaxel-Eluting Stent (TAXUS™) or an otherwise identical uncoated bare metal stent (EXPRESS™). Geisinger Medical Center, Sub-Investigator, Completed.

52. SHINE- A randomized Dose Ranging Study of Hexadecasaccharide including Active Control, in Patients with Unstable Angina or Non-ST –segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention. Geisinger Medical Center, Sub-Investigator, Completed.

53. AMIHOT II - TherOx® AO System AMIHOT II Clinical Trial-A Prospective, Multi-Center, Randomized Study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute Myocardial Infarction Patients with Successful Reperfusion (FIA PCE) ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download